Welcome to our dedicated page for enGene Therapeutics news (Ticker: ENGN), a resource for investors and traders seeking the latest updates and insights on enGene Therapeutics stock.
enGene Holdings Inc. (NASDAQ: ENGN) is a clinical-stage, non-viral genetic medicines company whose news flow centers on its lead investigational therapy, detalimogene voraplasmid, for high-risk non-muscle invasive bladder cancer (NMIBC). Company announcements frequently highlight clinical data from the ongoing Phase 2 LEGEND trial, regulatory interactions, and manufacturing readiness for this novel bladder-instilled genetic medicine.
Investors following ENGN news can expect updates on preliminary efficacy and safety results from the LEGEND pivotal cohort and additional cohorts, including complete response rates at various time points and treatment-related adverse event profiles. enGene also reports on changes to trial endpoints following discussions with the U.S. Food and Drug Administration, as well as participation in programs such as the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program.
News releases regularly cover capital markets activities, such as underwritten public offerings of common shares and pre-funded warrants, along with liquidity updates and financial results. Governance and leadership developments, including the appointment of new board members and the hiring of a Chief Medical Officer with extensive bladder cancer experience, are also disclosed through company press releases and related Form 8-K filings.
Because detalimogene has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, regulatory and clinical milestones are key themes in enGene’s communications. For users tracking ENGN, this news page aggregates company-issued updates on clinical progress, FDA designations and programs, financing transactions, and corporate governance developments, offering a centralized view of material events that may shape the company’s development trajectory.
enGene Holdings Inc. (Nasdaq: ENGN) has granted an inducement equity award to Joan Connolly, the company's new Chief Technology Officer. The award, granted on October 21, 2024, consists of a non-qualified stock option to purchase 210,000 common shares at an exercise price of $9.83 per share, equal to the closing price on the grant date.
The stock option has a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. This grant was made outside of enGene's 2023 Incentive Equity Plan but will have consistent terms and conditions. The award was approved by the independent Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4).
enGene Holdings Inc. (Nasdaq: ENGN) has announced key leadership changes to strengthen its executive team. Joan Connolly has been appointed as Chief Technology Officer (CTO), bringing over 30 years of experience in CMC development, manufacturing management, and regulatory filings. Anthony Cheung, Ph.D., co-founder and former CTO, will transition to the role of Chief Scientific Officer.
These appointments come as enGene advances its lead investigational product, detalimogene voraplasmid, through a pivotal study for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis). The company anticipates filing a Biologics License Application (BLA) in mid-2026.
Ms. Connolly's expertise is expected to be important in driving the late-stage clinical asset towards commercialization. Dr. Cheung, instrumental in developing enGene's DDX platform, will focus on expanding the technology's applications.
enGene Holdings Inc. (Nasdaq: ENGN) has reported the grant of inducement equity awards to seven newly-hired employees on September 30, 2024. The awards consist of non-qualified stock options to purchase a total of 183,000 common shares at an exercise price of $6.60 per share, equal to the closing price on the grant date. Each option has a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. The grants were made by the Company's independent Compensation Committee as an inducement for employment, in accordance with NASDAQ Listing Rule 5635(c)(4).
enGene Holdings Inc. (Nasdaq: ENGN) announced preliminary data from the pivotal cohort of the LEGEND study for detalimogene voraplasmid, their lead investigational product for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis). The data showed:
- 71% Complete Response (CR) rate at any time
- 67% CR rate at three months
- 47% CR rate at six months
- Favorable tolerability with no drug-related discontinuations
The results are consistent with Phase 1 findings, supporting detalimogene's potential as a foundational therapy for NMIBC. The company plans protocol refinements to potentially enhance clinical benefits. Detalimogene's profile, including ease of handling and administration, minimal storage requirements, and lack of post-procedural patient restrictions, positions it as a promising treatment option, especially for community practice settings where over 70% of urologists practice.
enGene Holdings Inc. (Nasdaq: ENGN) reported its Q3 2024 financial results and provided a business update. The company, focused on developing detalimogene voraplasmid for high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), remains on track to release preliminary LEGEND study data in September 2024. Key financial highlights include:
- Cash and cash equivalents of $257.7 million, providing runway into 2027
- Total operating expenses of $16.8 million for Q3 2024
- Net loss of $14.1 million, or $0.32 per share
The company also announced leadership changes, including Ron Cooper joining as CEO and the promotion of Dr. Raj Pruthi to Chief Medical Officer.
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, announced its participation in three upcoming investor conferences in September 2024. The company's lead program, detalimogene voraplasmid, is currently in a pivotal study for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis).
The conferences include:
- Morgan Stanley 22nd Annual Healthcare Conference on September 5
- Wells Fargo Healthcare Conference on September 6
- H.C. Wainwright 26th Annual Global Investment Conference on September 11
Presentations will be given by Ron Cooper (CEO), Raj Pruthi (CMO), and Alex Nichols (COO). Live webcasts will be available on the enGene website for 90 days after each event.
enGene Holdings Inc. (Nasdaq: ENGN) has granted an inducement equity award to its new CEO, Ron Cooper. The award consists of a non-qualified stock option to purchase 1,250,000 common shares at an exercise price of $8.81 per share, equal to the closing price on July 22, 2024. The option has a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over three years. This grant, approved by the independent Compensation Committee, is in accordance with NASDAQ Listing Rule 5635(c)(4) and is designed to incentivize Mr. Cooper as he joins the company.
enGene Holdings Inc. (Nasdaq: ENGN) has appointed Ron Cooper as its new Chief Executive Officer and Board member, effective July 22, 2024. Cooper succeeds Jason Hanson, who will remain as a strategic advisor. The company also promoted Dr. Raj Pruthi to Chief Medical Officer.
Cooper brings extensive experience in drug development and commercialization, having previously served as President and CEO of Albireo Pharma. He also spent nearly 30 years at Bristol-Myers Squibb in various leadership roles.
enGene is advancing EG-70, its lead product candidate for BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). The company believes EG-70 has the potential to be the most practical treatment option for high-risk NMIBC, offering a unique combination of efficacy, tolerability, and ease of administration.
enGene (Nasdaq: ENGN) reported its Q2 2024 results, showing significant financial and strategic updates. The company has expanded its LEGEND study of EG-70 into high-risk papillary-only NMIBC and plans to release interim data by September 2024. enGene secured a $200 million private placement in February and has $264.8 million in cash as of April 2024, expected to fund operations into 2027. However, its net loss increased to $15.0 million from $6.5 million YoY due to rising operating expenses. Additionally, the company announced key leadership changes and the deprioritization of the EG-i08 program for cystic fibrosis.
enGene Holdings, a clinical-stage genetic medicines company, announced that their CEO, Jason Hanson, will present a corporate overview at the Jefferies Global Healthcare Conference.
The event will take place in New York City on June 5, 2024, at 12:30 p.m. ET.
enGene's lead program, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
The presentation will be webcast live and archived on the enGene website for 90 days.